The original definition of hepatic veno-occlusive disease (VOD), which is still widely accepted, includes onset of the clinical syndrome before day +20 following highdose chemotherapy (HDC) and stem cell transplantation (SCT). We retrospectively identified four patients following HDC and SCT presenting with late onset VOD occurring at day +24, day +27, day +34 and day +42 post SCT. All patients had moderate VOD, with successful resolution of the VOD before day +100 with optimal supportive therapy. Common risk factors for VOD shared by all four patients included an older age (median age: 60 years), and use of a busulphan-containing regimen. Mean and maximum bilirubin levels for all patients during the VOD syndrome were 2.02, 1.76, 5.09, 2.87 mg/dl and 2.5, 2.2, 8.9 and 4.1 mg/dl, respectively, which correlated well with duration of VOD. All patients encountered platelet transfusion-dependent thrombocytopenia during VOD. Ursodeoxycholic acid was used as VOD prophylaxis beginning at a mean of 33 days prior to onset of VOD. As the cellular target of hepatic VOD is as yet unidentified, it is uncertain whether ursodiol or other common characteristics of patients with late onset VOD influence the pathogenesis and natural history of this disease. We believe that the uncommon clinical entity of late onset VOD, a potentially fatal regimen-related toxicity, should not be ignored as a diagnosis of liver disease after 3 or more weeks following HDC and SCT. Keywords: late onset VOD; high-dose chemotherapy; peripheral blood stem cell transplantation; ursodeoxycholic acid; VOD risk factors Hepatic veno-occlusive disease (VOD) is the leading cause of regimen-related morbidity and mortality in the first 2 months following high-dose chemotherapy (HDC) and bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT) 1 with an incidence ranging from 0% to 70%.
hepatomegaly and ascites or unexplained weight gain. 3 In the absence of histological confirmation, the combination of all three clinical features has been reported to have a specificity of 92% and sensitivity of 56%. 2, 4 It is now clear that VOD can develop in patients beyond day +20, thus necessitating that a time limit be omitted from the diagnostic criteria for VOD. 1, 2, 5 The entity of late onset VOD is not well described. Beyond the third and fourth weeks post SCT, the main differential diagnoses of liver injury include infective causes, acute GVHD, drug-related insults and recurrent disease. 6 Given that severe VOD is associated with a mortality approaching 100% by day +100 with no truly effective therapeutic options, 1, 3, 5, 7 early detection and institution of appropriate supportive measures are vital. VOD must not be ignored as a diagnostic consideration beyond 3 to 4 weeks post SCT in patients with clinical or biochemical liver dysfunction and/or weight gain. Here, we review the clinical characteristics of four patients who developed late onset VOD following HDC and PBSCT.
Patients and methods
We retrospectively identified four patients who had onset of VOD beyond day +20 following HDC and SCT from all SCT patients treated at the Massachusetts General Hospital (MGH) between 1993 and 1998. This represents 6.5% of BMT patients at the MGH who received conditioning with busulphan and cyclophosphamide (n = 62) and 1.2% of all BMT patients (n = 331) over this same period. All four patients were nursed in single rooms with laminar flow or HEPA filtered systems for their HDC and SCT.
In this retrospective analysis, we determined the timepoints at which the major features of VOD first occurred. We adopted the Jones criteria for the definition of VOD which are: the presence of jaundice (bilirubin Ͼ2.0 mg/dl) and two of the following clinical criteria: hepatomegaly and/or right upper quadrant pain, ascites, or у5% weight gain above admission weight. 1, 5 All four patients met the clinical criteria, with histological confirmation of VOD in two patients. In addition to routine blood investigations, viral serologies including hepatitis B, C and cytomegalovirus (CMV) serologies, a full coagulation screen and an abdominal ultrasound (U/S) were also performed at the onset of liver dysfunction and abdominal symptoms. A computer tomogram (CT) scan of the abdomen was performed in two cases (RL and HT) and doppler U/S in two cases (RL and EP). All four patients received oral ursodeoxycholic acid (ursodiol) 300 mg three times per day beginning on days −7 or −8 pre-transplant which was tapered to twice a day as outpatients as part of VOD prophylaxis. All patients also received standard oral antimicrobial prophylaxis of acyclovir, fluconazole and ofloxacin from the start of HDC and SCT until the resolution of neutropenia. Oral trimethoprim-sulfamethoxazole prophylaxis was continued until day +100 (stopped during neutropenia) for all four patients. Irradiated, leukofiltered packed red blood cells and platelets were transfused to maintain a haematocrit Ͼ25% and a platelet count Ͼ20 × 10 9 /l. We defined the point of resolution of VOD as the day clinical signs and symptoms of VOD resolved. The characteristics of the four patients with late onset VOD are described below.
Patient RL
Patient RL is a 57-year-old male with relapsed diffuse large cell lymphoma who received preparative therapy with busulphan (Bu) 1 mg/kg every 6 h for 14 doses and cyclophosphamide (Cy) 60 mg/kg for 2 days followed by 1.66 × 10 7
CD34
+ autologous peripheral blood stem cells/kg. He was empirically treated with i.v. ceftazidime and vancomycin on day +7 for a low grade fever, and discharged on transplant day +11. On day +26, he was readmitted with a 2 day history of right upper quadrant pain and 1 week of increasing skin bruising and thrombocytopenia requiring platelet transfusions. On admission, he had tender hepatomegaly of 5 cm, ascites and a platelet count of 8 × 10 9 /l. Abnormal alanine transaminase (ALT) and serum alkaline phosphatase (SAP) results were first noted on day +27 (92 U/l and 151 U/l, respectively, prior to a rise in total bilirubin levels to Ͼ2 mg/dl on day +34. Both U/S and a CT scan of the abdomen confirmed ascites only. A doppler U/S showed no evidence of inferior vena caval, portal or splenic thrombosis and revealed reverse flow in the portal vein and slowed flow through the splenic vein with no varices. He was treated with fluid restriction, low dose i.v. dopamine, furosemide, spironolactone and his ursodiol was continued. His VOD resolved on day +50, and he is currently alive and in remission at day +179 post SCT.
Patient EP
Patient EP, a 58-year-old male with multiple myeloma in first partial remission, received the same BuCy preparative regimen followed by the infusion of 2.65 × 10 7 CD34 + peripheral blood stem cells/kg. His post-SCT course was marked by an AST rise to 56 U/l, mucositis requiring morphine and i.v. empirical vancomycin and ceftazidime were added for neutropenic fever. He was discharged on day +13, but readmitted on day +23 with anorexia, peripheral oedema and rising bilirubin levels over the previous 4 days. Clinically, he had nontender hepatomegaly (2 cm) and ascites. An abnormal ALT was noted on day +22 at 82 U/l, preceding a rise in total bilirubin Ͼ2 mg/dl by 2 days. A raised SAP was apparent on day −7 (137 U/l). An abdominal ultrasound confirmed only ascites and a thickened gall bladder. Doppler U/S showed normal venous flow. On readmission, his platelet count was 88 × 10 9 /l. A percutaneous liver biopsy confirmed the diagnosis of hepatic VOD with profound panlobular congestion, oedema and haemorrhage into cords and subtotal central vein occlusion by cell debris and oedema fluid. His VOD resolved on day +32 following supportive care, and he is alive with progressive disease at day +896 post SCT.
Patient PD
Patient PD, a 66-year-old female with follicular and diffuse mixed small and large cell lymphoma in partial remission, received Bu 1 mg/kg every 6 h for 16 doses and Cy 60 mg/kg daily for 2 days followed by autologous PBSCT of 8.74 × 10 6 CD34 + cells/kg. She had only mild mucositis and was discharged on day +13. On day +25, she was readmitted for right upper quadrant pain, fatigue and anorexia, requiring a wheelchair. She was found to have tender hepatomegaly (2 cm), ascites and thrombocytopenia (3 × 10 9 /l). Her ALT and SAP were both first raised on day +22 at 118 U/l and 152 U/l, respectively, prior to onset of VOD and total bilirubin rise to Ͼ2 mg/dl on day +27. Her viral serologies were negative apart from a weakly positive CMV antigenemia, for which i.v. gancyclovir was started for a presumed CMV hepatitis. Abdominal U/S revealed a fatty liver, a thickened gall bladder, normal portal venous blood flow and ascites. On day +32, a percutaneous liver biopsy was performed which confirmed acute hepatic VOD with centrilobar haemorrhage and central vein periluminal oedema and luminal narrowing. Viral studies by immunohistochemistry and electron microscopy were negative. Her VOD resolved clinically on day +42 and she remained stable upon discharge and is alive on day +1079 post SCT but has relapsed.
Patient HT
Patient HT, a 61-year-old female with relapsed diffuse mixed cell lymphoma, received the same BuCy regimen as the first two patients followed by the infusion of 4.73 × 10 7
CD34
+ autologous PBSC/kg. She received empirical i.v. ceftzadime and vancomycin for neutropenic fever and had a prominent engraftment syndrome on day +10 with fever, chills and transient hypotension which responded to i.v. fluids and steroid therapy. She was discharged on day +17. On day +37, she received her back-up bone marrow following slow haematopoietic recovery requiring frequent platelet transfusions. On day +41, she presented with fatigue, anorexia and an increasing abdominal girth. She was found to have nontender hepatomegaly (2 cm), ascites, peripheral oedema and thrombocytopenia (9 × 10 9 /l). Apart from a rising total bilirubin Ͼ2 mg/dl from day +42, she did not have any liver function abnormalities throughout. Chest X-ray showed bilateral small pleural effusions and two-dimensional echocardiogram showed a normal left ventricular ejection fraction of 75%. A CT scan of the abdomen showed no change in her residual lymphomatous mass but there were new ascites and pleural effusions. A pleural aspirate and biopsy revealed an exudate with cytology negative for malignancy. Supportive treatment with fluid restriction, i.v. renal dose dopamine and diuretics were instituted and her VOD resolved clinically on day +80. She 
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is day +162 post SCT with relapsed disease and recently completed anti-CD20 monoclonal antibody therapy.
Results
The four patients described here had the onset of hepatic VOD at days +34, +24, +27 and +42 post SCT with the mean time to onset of VOD at 32 days (Table 1) . By definition, all four patients had moderate VOD, and appropriate treatment resulted in the successful resolution of VOD in each case. The median age is 60 years (range 57-66 years) with two males (RL, EP) and two females (PD, HT). In addition to specific VOD symptoms, anorexia and fatigue were significant early symptoms in each case. All patients presented with weight gain but only HT had a weight gain of у5% from her pretransplant weight (Table 1) . Ascites was confirmed radiologically in all patients. Radiologic features characteristic but not pathognomonic of VOD were identified in our series including thickened gall bladder wall (EP and PD) and reversal of venous blood flow (RL) on U/S examination of the abdomen. 6 Histological confirmation of VOD was obtained in two patients (EP and PD). All patients had haematologic malignancies and received the same conditioning regimen with HD BuCy followed by autologous PBSCT. Three of the four patients required i.v. ceftazidime and vancomycin for neutropenic fever. No patients developed fungal infections within the week prior to HDC and SCT. Fevers were not present in any of the patients during the VOD period and i.v. amphotericin B was not administered during the peritransplant or VOD periods. All four patients received ursodiol with a median duration of VOD prophylaxis of 33 days (range 18-49 days) prior to onset of VOD (Table 2) . Hepatitis B and C serologies pre-SCT and at suspicion of VOD were negative in Table 2 Bilirubin levels and duration of VOD all patients and none of the patients had hyperbilirubinaemia, pre-exisiting liver disease or malignant involvement of the liver prior to VOD onset. Patient PD was the only patient with CMV antigenemia during the evaluation for VOD and was initially treated with i.v. gancyclovir for presumed CMV hepatitis. During the duration of clinical VOD which ranged from 8 to 21 days, the mean bilirubin levels of the four patients were 2.02 ± 0.33, 1.76 ± 0.27, 5.09 ± 1.52 and 2.87 ± 0.8 mg/dl and maximum bilirubin levels were 2.5, 2.2, 8.9 and 4.1 mg/dl, respectively (Table 2 and Figure 1) . The time to total bilirubin recovery to Ͻ2 mg/dl, following onset of VOD were 7 days, 5 days, 32 days and 27 days, respectively ( Table 2 ). The mean platelet count in this same period for RL, EP, PD and HT were 20 ± 5.6, 82 ± 6.29, 64 ± 25.82 and 24 ± 12.33 × 10 9 /l, respectively, and multiple platelet transfusions were required in all four patients for a platelet count below 20 × 10 9 /l or evidence of bleeding with a platelet count of Ͻ50 × 10 9 /l. No evidence for multi-organ system involvement (cardiac, renal, pulmonary or central nervous system) was observed in any patient. Only patient HT had extraabdominal involvement in the form of bilateral non-malignant pleural effusions with no evidence of cardiac or pulmonary disease. Creatinine levels were normal for all four patients prior to and throughout the period of clinical VOD. The SAP levels of RL, EP and PD were elevated from day +27 (151 U/l), day −7 (137 U/l) and day +22 (152 U/l), respectively, and gradually increased on the day of VOD onset (total bilirubin у2 mg/dl) to levels of 171 U/l, 402 U/l and 263 U/l, respectively. Levels continued to increase throughout the VOD period and remained high even following resolution of VOD symptoms and normalisation of total bilirubin levels. The ALT levels were elevated in RL, EP and PD 7 days (92 U/l), 2 days (82 U/l) and 5 days (118 U/l) prior to diagnosis of VOD, rising to 174 U/l, 107 U/l and 290 U/l at the onset of VOD.
Discussion
Hepatic VOD induced by HDC and SCT is a complex clinical syndrome originally described as occurring earlier than VOD following liver radiation and ingestion of natural toxic pyrrolizidine alkaloids, the latter insult resulting in the first descriptions of VOD over 40 years ago. [8] [9] [10] [11] The incidence of VOD is highly variable. In a recent prospective study by Carreras et al 12 of 1652 patients, only 87 cases (5.3%) of VOD were reported. The incidence of late onset VOD is not known. We adopted the well accepted definition of clinical VOD of Jones et al, 5 which, appropriate for this study, did not establish a time limit for onset of VOD. Nevertheless, in their review of 235 consecutive patients following SCT, all patients met the criteria for hepatic VOD by day +21. In a large cohort study of 355 patients by McDonald et al, 3 the median day when bilirubin levels were Ͼ2 mg/dl was 6 days (2-9 days). In the International Bone Marrow Transplant Registry study by Rozman et al 2 which analysed 1717 patients, 95 patients were identified to have VOD (median time to onset of VOD at 13 days post transplant) including a minority of cases where VOD occurred later than day +20. Late onset VOD is thus a real but rare disease entity with little current literature reporting on this clinical syndrome.
Late onset VOD following SCT in our series occurred in an older age group of patients. Older age is well established as a patient-related risk factor for VOD. 2, 4 With increasing numbers of older patients receiving HDC and SCT, VOD incidence, and perhaps also late onset VOD, may increase. All four patients also received conditioning with BuCy followed by autologous PBSCT. In all four patients with late onset VOD, two commonly established VOD risk factors were noted: older age and busulphancontaining regimen. 2, 6, 13, 14, 15 Peritransplant vancomycin treatment (RL, EP, HT) may also be a predisposing VOD risk factor, perhaps by precipitating a systemic inflammatory process resulting in liver injury. 16 The quinolone group of antibiotics used for antimicrobial prophylaxis (ofloxacin in our series) has also been shown to be a VOD risk factor in one study where BuCy was the conditioning regimen. Their ability to activate cytochrome p450 mixed function oxidase may influence the metabolism of cyclophosphamide, which requires cytochrome p450 for bioactivation, and thus increase local cyclophosphamide concentration near the acinar outlet with consequent toxicity to zone 3 hepatocytes. None of the patients had raised ALT levels during the week prior to HDC and SCT. 16 The raised ALT levels in three cases within 1 week preceding the onset of VOD may divert initial diagnostic attention towards more hepatitis-related causes of their liver dysfunction. The principles of supportive care in maintaining intravascular volume, adequate renal perfusion and minimising extravascular volume by sodium restriction, diuretic therapy and i.v. renal dose dopamine effected successful resolution of VOD by day +100 in all four patients. The cellular target of VOD is not yet identified, although it is known that VOD is associated with drugs that undergo hepatic metabolism. Although the complete mechanism of ursodiol remains unknown, its actions include replacing endogenous, toxic, hydrophobic bile acids in the liver with non-toxic, hydrophillic bile acids, 17 stabilising the hepatocyte cell membranes and also downregulating the class II region of the cell surface major histocompatibility complex. 15, 18 Ursodiol may also bind to the offending metabolite that inflicts hepatic endothelial damage. These actions may contribute to minimising hepatic venous endothelial damage and potentially alter the natural history of clinical VOD. The relatively lower mean and maximum bilirubin levels in our series may reflect the influence of ursodiol. It is possible that ursodiol may inhibit the early evolution of VOD in patients with predisposing VOD risk factors, resulting in a delayed onset of VOD in some patients. Following the double-blind randomized clinical trial by Essell et al 17 which demonstrated a beneficial role for ursodiol as prophylaxis for VOD following HDC and SCT, ursodiol use will become more commonplace as VOD prophylaxis. Whether this pharmacological modality will result in an increasing incidence of late onset VOD remains to be confirmed in larger studies.
In allogeneic BMT, the common notion that VOD occurs before day +20 and acute graft-versus-host disease (GVHD) usually occurs after day +20 may result in the clinician dismissing VOD from the differential diagnosis of liver disease occurring after day +20. 19 The characteristic clinical features of weight gain and ascites can help to distinguish VOD from acute GVHD. 13, 19 It is also believed that a rising SAP level is a more common feature of progressive GVHD than of VOD. 13 However, in three cases (RL, EP and PD), a significantly raised SAP preceded the onset of a total bilirubin Ͼ2 mg/dl, and SAP levels continued to increase and remained high even after the resolution of VOD.
There is now an increasing number of outpatient HDC and SCT procedures, more older patients undergoing SCT, 20 earlier hospital discharge post SCT and early return of care of post HDC and SCT patients to their referring community physicians once they are stable. With this change in management of SCT patients, 21 it is important that the poorly acknowledged entity of late onset VOD, a potentially fatal regimen-related complication, be considered in patients presenting with abnormal liver function tests, unexplained weight gain or even anorexia and fatigue 3 weeks or later following SCT.
